Merck's Keytruda prolongs NSCLC patients' lives in study; Endo nabs FDA OK for dissolving pain therapy, with warnings;

@FiercePharma: ICYMI from FiercePharmaAsia: Ranbaxy merger showing sharp cons as well as pros for Sun Pharma. Item | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Japan's says its mAb work with means a need for a $309M API plant expansion. Article | Follow @EricPFierce

@CarlyHFierce: SOMEbody got burned out on grammar by slide 82 of the $VRX presentation. "Why does R&O and Philidor have the same phone number?" | Follow @CarlyHFierce

> Merck & Co. ($MRK) touted top-line data showing that its immuno-oncology drug Keytruda helped certain patients with non-small-cell lung cancer live longer. Release

> Endo ($ENDP) and BioDelivery Sciences won FDA approval for a dissolvable pain treatment, Belbuca, but a side-effects warning could inhibit uptake. Report

> GlaxoSmithKline ($GSK) won European backing to expand approval of Volibris, a treatment for pulmonary arterial hypertension, to use in combination with other meds. Report

> Novartis' ($NVS) psoriasis med Cosentyx got a thumbs up from Europe's drug approval committee for new uses in ankylosing spondylitis and psoriatic arthritis. Report

> Rare disease specialist Alexion Pharmaceuticals ($ALXN) nabbed an FDA clearance for Strensiq, which treats hypophosphatasia, a genetic disorder. Release | Report

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@EmilyWFierce: ICYMI Friday: Kadcyla's miss in stomach cancer dents Roche's effort to reap more from new drugs. FiercePharma story | Follow @EmilyWFierce

> Healthcare, wellness drive Philips growth as it works to shed lighting, maintain cautious M&A strategy. Story

> Report: Buyer interest heating up for Swiss Dx company Unilabs. More

> Walgreens freezes partnership with Theranos amid testing fallout. Report

Biotech News

@FierceBiotech: ICYMI: AstraZeneca's gout drug wins faint praise from FDA advisers. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: Alexion wins priority review voucher with FDA OK of Strensiq. Report | Follow @JohnCFierce

@DamianFierce: This is an excellently reported /Philidor story that deserves a more alluring headline. Perhaps "One Weird Trick To Boost Drug Revenue," and then they could do like a quiz to "Find Your Philidor Alter-Ego" WSJ story | Follow @DamianFierce

> Endo and BDSI pick up FDA approval for a cheek-delivered pain drug. Story

> Vertex pays $105M to kick off gene editing pact with CRISPR Therapeutics. Article

> Key investor pushes for GSK breakup after pipeline fails to deliver. Report

Animal Health News

> Subway ups the ante on antibiotic-free meat pledge. More

> Lilly charts strong Q3 results bolstered by Novartis Animal Health addition. Item

> After downsizing and delaying IPO, Oasmia pulls off Nasdaq debut. Story

> New app offers remote veterinary visits for pet owners. Article

> Parnell shares advance on strong Q3 revenue growth. Report

Biotech IT News

> Big Pharma follows cash-strapped seniors onto the darknet. Story

> Silicon Valley's thrust into biotech sparks scramble for data scientists. Report

> J&J inks deal to access Nuevolution's informatics-enabled discovery platform. News

> Genentech deal continues big 2015 for in silico specialist Nimbus. Article

> Novartis, Qualcomm joint venture backs $6.5M Series A round for Science 37. More

Pharma Marketing News

> AbbVie faces the music with Express Scripts over FDA's Viekira Pak warning. Item

> J&J's Yondelis finally captures FDA nod, but path to big sales could be steep. More

> The eyes may have it, but pharma still needs convincing on branded visual comms. Report

> Sales reps need to bone up on tech skills as drug launches move digital. Story

> Biogen to put layoffs savings toward DTC, patient support for lagging Tecfidera. Article

And Finally... The British publisher Pearson tapped former Eli Lilly & Co. ($LLY) CEO Sidney Taurel as its new non-executive chairman. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.